期刊文献+

原发免疫性血小板减少症患者血栓发生情况及相关危险因素分析 被引量:13

The incidence and risk factors for thrombosis in primary immune thrombocytopenia
原文传递
导出
摘要 目的探讨原发免疫性血小板减少症(ITP)患者血栓发生情况及相关危险因素。方法对2005年12月至2017年12月在中国医学科学院血液病医院血栓止血中心住院治疗的3 225例ITP患者进行回顾性分析。结果 共46例患者(1.43%)发生血栓事件,中位发病年龄为54(26~83)岁,成人患者中〉40岁人群血栓发生率明显高于40岁以下人群[3.37%(40/1 187)对0.58%(6/1 030),P=0.000]。男、女性患者血栓发生率差异无统计学意义[1.53%(20/1309)对1.36%(26/1 916),P=0.187]。动脉血栓的发生率高于静脉血栓[1.12%(36/3 225)对0.22%(7/3 225),P=0.000]。82.61%(38/46例)患者发生血栓时PLT〈100×109/L。吸烟、高血压病、糖尿病及脾切除是ITP患者发生血栓的危险因素(P值分别为0.232、0.531);糖皮质激素、TPO治疗患者治疗在有无血栓事件的两组间比较差异无统计学意义(P值分别为0.064、0.075、0.531)。结论 对于中国人群,ITP疾病本身可能也是一种可伴发血栓的免疫性疾病,即使血小板水平低下仍可发生血栓事件;且具有明显的年龄分布特点;吸烟史、高血压病、糖尿病史及脾切除是发生血栓的危险因素。 Objective To probe the incidence and risk factors for thrombosis in Chinese immune thrombocytopenia through a retrospective analysis of the inpatients referred to the Blood Disease Hospital, CAMS & PUMC.Methods A retrospective survey of 3 225 patients with ITP from October 2005 to December 2017 was performed, the clinical data of the patients with thrombosis were collected to analyze the causes, diagnosis, treatment and prognosis.Results A total of 46 patients experienced a thrombotic event with a prevalence of 1.43%(46/3 225 cases) with the median age of thrombosis as 54 years (26-83) years, the prevalence of thrombosis was 3.37% (40/1 187 cases) in〉40 years old, which was significantly higher than 0.58% (6/1 030 cases) in those under 40 years old, in adults (P=0.00). There were 20 males and 26 females, there was no statistical difference in the incidence of thrombosis between males and females[1.53% (20/1 309) vs 1.36% (26/1 916), P=0.187]; The prevalence of arterial thrombosis was 1.12% (36/3 225) higher than venous thrombosis[0.22% (7/3 225), P=0.00]when 82.61%(38/46 cases) of patients with PLT〈100×109/L. Post-splenectomy are risk factors for thrombosis in ITP patients, P values was 0.022, There was no statistical difference in the presence or absence of thrombotic events whether received glucocorticoid or TPO/TPO-Ra treatment, the P values were 0.075 and 0.531, respectively.Conclusions In Chinese population, ITP disease maybe with a higher risk of thrombosis, there was no positive correlation between thrombosis and platelet level; and had obvious age distribution characteristics. The history of tobacco, hypertension, diabetes and post-splenectomy are risk factors for thrombosis in ITP patients.
作者 黄月婷 刘晓帆 陈云飞 付荣凤 刘葳 薛峰 张磊 杨仁池 Huang Yueting;Liu Xiaofan;Chen Yunfei;Fu Rongfeng;Liu Wei;Xue Feng;Zhang Lei;Yang Renchi(Institute of Hematology and Blood Disease Hospital,CAMS & PUMC,Tianjin 300020,China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2018年第11期942-946,共5页 Chinese Journal of Hematology
关键词 血小板减少症 血栓 治疗 Primary immune thrombocytopenia Thrombosis Therapy
  • 相关文献

参考文献2

二级参考文献62

  • 1ProvanD, StasiR, NewlandAC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood,2010,115(2):168-186.
  • 2NeunertC, LimW, CrowtherM, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood,2011,117(16):4190-4207.
  • 3British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol,2003,120(4):574-596. doi:10.1046/j.1365-2141.2003.04131.x.
  • 4WeiY, JiXB, WangYW, et al. High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial[J]. Blood,2016,127(3):296-302. doi:10.1182/blood-2015-07-659656.
  • 5WangS, YangR, ZouP, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J]. Int J Hematol,2012,96(2):222-228. doi:10.1007/s12185-012-1124-8.
  • 6BusselJB, ChengG, SalehMN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura[J]. N Engl J Med,2007,357(22):2237-2247. doi:10.1056/NEJMoa073275.
  • 7BusselJB, ProvanD, ShamsiT, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, doubleblind, placebo-controlled trial[J]. Lancet,2009,373(9664):641-648. doi:10.1016/S0140-6736(09)60402-5.
  • 8ChengG, SalehMN, MarcherC, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study[J]. Lancet,2011,377(9763):393-402. doi:10.1016/S0140-6736(10)60959-2.
  • 9SalehMN, BusselJB, ChengG, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study[J]. Blood,2013,121(3):537-545. doi:10.1182/blood-2012-04-425512.
  • 10KuterDJ, BusselJB, LyonsRM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial[J]. Lancet,2008,371(9610):395-403. doi:10.1016/S0140-6736(08)60203-2.

共引文献428

同被引文献109

引证文献13

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部